We serve Chemical Name:3-(Trifluoromethyl)thiophene-2-carboxylic acid CAS:767337-59-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(Trifluoromethyl)thiophene-2-carboxylic acid
CAS.NO:767337-59-7
Synonyms:3-(trifluoromethyl)thiophene-2-carboxylic acid
Molecular Formula:C6H3F3O2S
Molecular Weight:196.14700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:65.54000
Exact Mass:195.98100
LogP:2.46510
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(trifluoromethyl)thiophene-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(trifluoromethyl)thiophene-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(trifluoromethyl)thiophene-2-carboxylic acid Use and application,3-(trifluoromethyl)thiophene-2-carboxylic acid technical grade,usp/ep/jp grade.
Related News: What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. 3-(Trifluoromethyl)thiophene-2-carboxylic acid manufacturer From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 3-(Trifluoromethyl)thiophene-2-carboxylic acid supplier This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. 3-(Trifluoromethyl)thiophene-2-carboxylic acid vendor First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 3-(Trifluoromethyl)thiophene-2-carboxylic acid factory What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL.
